The Blood Lead Levels of Children and the Loss of Ca\textsuperscript{2+} from Neurons Owing to Lead

Yifei Duan\textsuperscript{1,2}, Hua Shi\textsuperscript{1,2} and Yongmei Jiang\textsuperscript{1,2,*}

Abstract: In order to understand current blood lead levels (BLLs), we investigated the BLLs of children in Sichuan Province from 2011 to 2020. We then monitored the treatment effects of calcium in children with high BLLs to assess their treatment status. Finally, we explored the effects of lead on Ca\textsuperscript{2+} through in-situ experiments. Whole blood samples were used for BLL tests. The BLLs of 76,362 children aged 0–7 years were measured using atomic absorption spectrometry. The median BLL was 35 µg/L (interquartile range: 28–47). The BLLs were significantly higher in boys than in girls ($p < 0.001$). The BLLs generally decreased annually and increased with age. The overall prevalence of BLLs $\geq 100$ µg/L was 1.20%. The children with high BLLs received subsequent check-ups, and the median time required for effective treatment was 18 months. We observed that lead exposure led to a gradual and persistent loss of Ca\textsuperscript{2+} levels in neurons of mice brain slices, and the effect did not subside immediately even after the lead was removed. China has made rapid progress in pediatric healthcare, but the treatment status remains unsatisfactory. Because lead causes an irreversible loss of Ca\textsuperscript{2+}, there is an urgent need to develop new standardized treatments to reduce the treatment duration.

Keywords: blood lead levels; treatment status; calcium supplement; Ca\textsuperscript{2+} imaging

1. Introduction

Lead is a non-biodegradable, malleable, noncorrosive heavy metal. As it has favorable properties for many man-made applications, it has been used for centuries. Lead exists in our daily lives in the composition of various pigments, glazes, paints, and plastic products. It can also be discharged into the atmosphere during the mining or processing of lead or lead-bearing ores as well as amidst the manufacturing of lead products and batteries. Unfortunately, lead may enter the human body through air, water, and food, and it can accumulate in the organs and further affect their functions \cite{1,2}. Young children are more likely to suffer the impacts of lead exposure owing to their hand-to-mouth habits, weak immune system, incomplete blood–brain barrier, and higher absorption and lower discharge capacity \cite{3,4}. Even though the incidence of lead poisoning in children has recently decreased, the hazards of lead exposure, such as deficits in neural plasticity, learning, and memory, should not be underestimated \cite{5,6}. Lead-induced damage in the prefrontal cerebral cortex, hippocampus, and cerebellum can lead to a variety of neurologic disorders. High BLLs and lead poisoning remain as serious concerns, and effective methods to avoid lead exposure are yet to be developed. Early screening, standardized treatment, and regular follow-ups may prove useful in children at high risk of lead exposure.

Two documents titled “The Children Lead Acidosis and Lead Poisoning Prevention Guide” and “Children’s Blood Lead and Lead Poisoning Classification Principles” \cite{7} were issued by the Ministry of Health in China as guidelines for the prevention, diagnosis, and treatment of lead poisoning. Lead poisoning has been classified into three
grades, namely severe (BLLs ≥ 450 µg/L), moderate (250 ≤ BLLs ≤ 449 µg/L), and mild (200 ≤ BLLs ≤ 249 µg/L) lead poisoning, and BLLs between 100 and 199 µg/L for two consecutive tests can be considered as high blood lead. As per the abovementioned documents, treatment for children with 100 ≤ BLLs ≤ 249 µg/L includes keeping the children away from lead pollution sources, paying attention to hygiene, and nutrition intervention; for children with BLLs ≥ 250 µg/L, additional chelation therapy is also needed. The documents detail chelation therapy for children with moderate and severe lead poisoning; however, they do not specify standardized nutritional interventions for children with high blood lead and mild lead poisoning. An oral calcium supplement is often used to address high blood lead and mild lead poisoning in clinical practice. For children with BLLs between 100 and 250 µg/L, taking an oral calcium supplement for more than half a year may slowly reduce the BLL. Long-term exposure to high BLLs can greatly affect the growth and development of young children, especially their neural systems. Considering the great hazard of lead toxicity, the Centers for Disease Control and Prevention, USA, ascertained the BLL that should prompt public health actions as 100 µg/L in 1991, and they subsequently adjusted it to 50 µg/L, highlighting, however, that no levels of lead may be considered “safe” for children. Studies have proved that even BLLs that are lower than the cut-off may affect the development of the neural system of a child [8]. Therefore, the grading and treatment strategy for lead poisoning and high blood lead, respectively, in China may need to be modified and improved.

Moreover, the mechanisms by which lead disrupts the brain and its behavior are complex and remain poorly understood and thus are active research topics. The antagonistic behavior between lead and calcium is of particular significance. Lead binds to the sites at which calcium typically acts and enters the cells through calcium channels; thus, it substitutes for calcium in the inhibition and/or activation of calcium-dependent processes [9]. Lead binds to voltage-gated calcium channels and reduces the influx of calcium, thereby reducing the release of neurotransmitters [10–12]. The disruption of normal neurotransmitter release may result in a variety of consequences for the brain and its behavior depending on the specific neurotransmitter and its location in the brain. To observe the interaction between lead and Ca\(^{2+}\) in the cerebral cortex and to discern the effects of lead on the influx of calcium, the neurons were observed using dynamic Ca\(^{2+}\) imaging under lead exposure. Ca\(^{2+}\) imaging provides a wide range of applications in neuroscience because it can measure neuronal dynamics and network activity. It monitors network-level changes in neurons. Ca\(^{2+}\) imaging typically reveals some spontaneous neuronal firing by detecting dramatic changes in the level of Ca\(^{2+}\) [13]. Therefore, Ca\(^{2+}\) imaging not only reflects the change of Ca\(^{2+}\)-level in neurons caused by lead but also reflects the effect of lead on neuron function.

Lead exposure in children in Sichuan Province has not been reported recently; therefore, the current study aims to update the BLL data for children aged 0–7 years in this area based on the past decade and trace the efficiency of treatment in children with high BLLs. Moreover, the antagonistic effects of lead against Ca\(^{2+}\) in neurons under lead exposure are observed using Ca\(^{2+}\) imaging.

2. Materials and Methods

2.1. Ethics Statement

Ethics approval was obtained from the Medical Ethics Committee of West China Second University Hospital of Sichuan University (protocol 2021176). All experiments using mice were approved by the Animal Research Committee at the West China Second University Hospital of Sichuan University (protocol 2021048A).

2.2. Participants

The study recruited 76,362 children who received regular health check-ups at the outpatient clinic of West China Second University Hospital of Sichuan University between 2011 and 2020. All the children were residents of Sichuan Province. For the evaluation of
the treatment effects of an oral calcium supplement in children with high blood lead and mild lead poisoning. 73 patients (100 ≤ BLLs ≤ 249 µg/L) received subsequent check-ups.

2.3. Animals

BALB/c mice were selected as experimental subjects. Live cell imaging was performed to assess the dynamics of Ca^{2+} signals inside neurons in the cerebral cortex. Deionized drinking water and food were freely accessible to the mice throughout the study. The mice were housed at a constant temperature (22 ± 2 °C) and relative humidity (50% ± 10%) with a 12-h light/dark cycle.

2.4. BLL Test

All tests were performed in the Department of Laboratory Medicine, West China Second University Hospital of Sichuan University, China. This laboratory subscribes to the National System of External Quality Assessment and the College of American Pathology. Whole blood samples were drawn from the children into lead-free vacutainer tubes that contained sodium heparin. The BLLs were analyzed using atomic absorption spectrometry (BH2100, Bohui Co., Ltd., Beijing, China) with the matched calibrator and quality control reagent provided by the manufacturer. Quality control reagent was tested before, during, and after sample testing to ensure the accuracy of the results. We participate in the National Health Commission’s external quality assessment of BLL tests every year. Only laboratories that pass the assessment can continue their tests.

2.5. Follow-Up

Currently, children with BLLs of 100 µg/L or higher need to be treated in China. Treatment is divided into two categories. The first is chelation therapy for children with BLLs greater than or equal to 250 µg/L. The second is oral calcium supplement for children with BLLs less than 250 µg/L. Because chelation therapy has been proven to be a rapid and effective treatment, only oral calcium supplementation was evaluated in this study. In order to evaluate the treatment effects in children with high blood lead and mild lead poisoning, 73 patients (100 ≤ BLL ≤ 249 µg/L) aged 2–7 years received subsequent check-ups, among whom 54 had 100 ≤ BLL ≤ 199 µg/L, and 19 had 200 ≤ BLL ≤ 249 µg/L. Children with 100 ≤ BLL ≤ 199 µg/L were given 330 mg calcium per day, and children with 200 ≤ BLL ≤ 249 µg/L were given 440 mg calcium per day. After a period of treatment, BLLs of the children were tested again in our hospital. Treatment was considered effective if BLL was lower than 100 µg/L and ineffective if still greater than or equal to 100 µg/L.

2.6. Ca^{2+} Imaging

Ca^{2+} imaging is a powerful tool to measure neuronal dynamics and network activity [13]. First, artificial cerebrospinal fluid (aCSF) and Ca^{2+} stain were prepared. The aCSF comprised 7.25 g NaCl, 0.335 g KCl, 1.8 g glucose, 0.144 g NaH_{2}PO_{4}, 2.18 g NaHCO_{3}, 0.222 g CaCl_{2}, and 0.095 g MgCl_{2} (Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai, China) in 1 L distilled water. The Ca^{2+} stain comprised 15 µL Pluronic F-127 (100 mg in 0.5 mL dimethylsulfoxide (DMSO)) (Shanghai Aladdin Biochemical Technology Co., Ltd., Shanghai, China), 15 µL Fluo-4 AM (1.4 µL in 13.6 µL DMSO) (Biyuntian Biotechnology Co., Ltd., Shanghai, China), and 3 mL aCSF. Second, solutions with 100 and 50 µg/L concentrations of lead were prepared by dissolution of lead acetate with aCSF, producing 100 and 50 µg/L lead solutions of 500 mL.

Mice were euthanized on post-natal day 21 via cervical dislocation, and their whole brains were isolated and harvested. Coronal slices of somatomotor areas in the brain were cut at a thickness of 100 µm in aCSF, which maintained a temperature of 37 °C and bubbled with 95% O_{2}/5% CO_{2}. Brain slices were incubated in the Ca^{2+} stain for 30 min at 37 °C, and they were then washed three times with aCSF for 10 min. Finally, the coronal slices were observed using a positive fluorescence microscope (A1R + MP, Eclipse 80i, Nikon Corp., Tokyo, Japan). The result was recorded by taking pictures every 5 s. Fifteen subjects
were equally divided into three groups according to the concentrations of lead solutions: 100 µg/L, 50 µg/L, and control groups (only aCSF). The coronal slices were stabilized for 2 min in aCSF, then aCSF was replaced with lead solutions in the 100 µg/L group and 50 µg/L group. After the coronal slice was soaked in the lead solution for 30 s, the lead solution was switched with aCSF. The experiment ended after 15 min of observation in aCSF. The control group was observed only in aCSF. Ca²⁺ imaging was repeated three times.

### 2.7. Statistical Analysis

The median and interquartile range (IQR) were used to describe the BLL in children, which was not normally distributed. The Kruskal–Wallis test was used to compare the BLLs of different age groups, and the Mann–Whitney U test was used to compare the data of two groups. The chi-square was used to compare the boy to girl ratios between different years. The treatment efficacy of oral calcium supplements in children with high BLLs was analyzed using the Kaplan–Meier method. All analyses were performed using SPSS 19.0 (IBM, Inc., New York, NY, USA). All statistical tests were two-sided, and a \( p \)-value less than 0.05 was considered statistically significant.

### 3. Results

#### 3.1. Median BLL

A total of 76,362 children, among whom 43,993 (57.6%) were boys and 32,369 (42.4%) were girls, were included in the study (Table 1). The overall boy to girl ratio was 1.36. The boy to girl ratio in each year were as follows: 1.36 in 2011, 1.37 in 2012, 1.32 in 2013, 1.34 in 2014, 1.30 in 2015, 1.38 in 2016, 1.37 in 2017, 1.31 in 2018, 1.48 in 2019, and 1.41 in 2020. The boy to girl ratios were not significantly different from 2011 to 2018 (\( \chi^2 = 6.82, p = 0.448 \)). The boy to girl ratio in 2019 was significantly higher than those in 2011–2018 (\( \chi^2 = 16.41, p = 0.037 \)). The average age was 3.3 ± 1.8 years old. The distribution of BLL was positively skewed. The median BLL was 35 µg/L (IQR: 28–47), and the range was 8–963 µg/L.

Table 1 represents the BLLs of boys and girls in different years; the median BLL of boys was significantly higher than that of girls (\( p < 0.05 \)). The median BLLs for different age groups are illustrated in Table 2. The median BLL was lowest (32 µg/L) in the ~1 year group and highest (38 µg/L) in the ~6 and ~7 years groups (\( p < 0.001 \)). The median BLLs were not significantly different between the ~6 and ~7 years groups (\( Z = -0.22, p = 0.826 \)). Overall, the median BLLs increased with age in all children. Figure 1 shows the changes in the median BLL of different age groups from 2011 to 2020. The median BLLs in each year are as follows: 55 µg/L (IQR: 44–67) in 2011, 47 µg/L (IQR: 37–60) in 2012, 41 µg/L (IQR: 33–52) in 2013, 33 µg/L (IQR: 27–39) in 2014, 34 µg/L (IQR: 29–41) in 2015, 35 µg/L (IQR: 30–44) in 2016, 30 µg/L (IQR: 26–36) in 2017, 29 µg/L (IQR: 26–40) in 2018, 29 µg/L (IQR: 25–35) in 2019, and 27 µg/L (IQR: 24–31) in 2020.

**Table 1.** Comparison of BLLs between boys and girls from 2011 to 2020.

| Years | Boy N | Median (P25–P75) | N | Median (P25–P75) | p-Value |
|-------|-------|-----------------|---|-----------------|---------|
| 2011  | 4797  | 56 (45–68)      | 3525 | 53 (43–65)     | <0.001  |
| 2012  | 5818  | 49 (38–61)      | 4236 | 46 (36–58)     | <0.001  |
| 2013  | 4818  | 42 (34–54)      | 3655 | 40 (32–51)     | <0.001  |
| 2014  | 4899  | 33 (27–39)      | 3661 | 32 (27–38)     | <0.001  |
| 2015  | 5031  | 35 (29–42)      | 3861 | 34 (28–40)     | <0.001  |
| 2016  | 4286  | 36 (30–45)      | 3114 | 35 (29–42)     | <0.001  |
| 2017  | 4106  | 31 (26–36)      | 3000 | 30 (26–36)     | <0.001  |
| 2018  | 2800  | 33 (26–40)      | 2139 | 32 (26–40)     | 0.01    |
| 2019  | 2890  | 29 (25–35)      | 1957 | 28 (25–34)     | 0.009   |
| 2020  | 4548  | 27 (24–32)      | 3221 | 26 (23–31)     | <0.001  |
| Total | 43,993| 36 (28–48)      | 32,369| 35 (28–46)     | <0.001  |
The overall prevalence of BLLs ≥ 100 μg/L was 1.20%. The prevalence of ≥ 100 μg/L was consistent with that in the median BLLs. The overall prevalence of BLLs ≥ 0 μg/L was 21.56%. The prevalence of ≥ 0 μg/L is consistent with that in the median BLLs.

Table 2. The BLLs (μg/L) of children in different age groups during 2011–2020.

| Years | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | Median (P25–P75) N | p-Value |
|-------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|--------------------|---------|
| 2011  | 1575               | 48 (38–57)         | 1726               | 51 (42–62)         | 2220               | 56 (45–67)         | 901                | 59 (48–70)         | 663                | 60 (48–73)         | 658                | 61 (50–73)         | 579     | <0.001 |
| 2012  | 2210               | 45 (33–51)         | 2265               | 49 (38–61)         | 2323               | 51 (41–64)         | 1006               | 54 (43–66)         | 835                | 54 (44–68)         | 710                | 55 (45–68)         | 646     | <0.001 |
| 2013  | 1804               | 40 (30–46)         | 2051               | 42 (34–53)         | 1940               | 44 (35–57)         | 801                | 46 (38–57)         | 686                | 45 (38–57)         | 632                | 45 (38–57)         | 529     | <0.001 |
| 2014  | 1572               | 30 (24–34)         | 1983               | 33 (28–39)         | 2173               | 34 (30–40)         | 786                | 35 (31–41)         | 710                | 37 (33–42)         | 732                | 37 (33–42)         | 604     | <0.001 |
| 2015  | 1797               | 32 (25–37)         | 1918               | 35 (29–42)         | 2318               | 36 (32–44)         | 884                | 37 (33–44)         | 741                | 37 (33–46)         | 576                | 38 (35–47)         | 658     | <0.001 |
| 2016  | 1275               | 32 (26–39)         | 1652               | 34 (29–43)         | 2002               | 37 (31–44)         | 850                | 37 (33–47)         | 588                | 37 (33–48)         | 525                | 39 (34–48)         | 508     | <0.001 |
| 2017  | 1311               | 30 (23–32)         | 1220               | 30 (25–34)         | 1767               | 32 (28–37)         | 811                | 32 (29–38)         | 729                | 33 (29–39)         | 673                | 34 (30–39)         | 595     | <0.001 |
| 2018  | 740                | 30 (24–37)         | 924                | 32 (25–39)         | 1260               | 32 (27–41)         | 606                | 32 (28–42)         | 534                | 34 (28–43)         | 464                | 35 (29–43)         | 411     | <0.001 |
| 2019  | 592                | 27 (23–32)         | 689                | 28 (24–33)         | 1131               | 28 (25–34)         | 593                | 29 (25–36)         | 600                | 29 (26–35)         | 600                | 30 (27–36)         | 642     | <0.001 |
| 2020  | 1176               | 26 (23–30)         | 1119               | 27 (23–30)         | 1608               | 27 (24–32)         | 915                | 27 (25–31)         | 980                | 27 (25–32)         | 989                | 28 (25–32)         | 982     | <0.001 |
| Total | 14,082             | 32 (26–43)         | 15,547             | 34 (27–46)         | 18,742             | 36 (28–48)         | 8212               | 37 (30–50)         | 7066               | 37 (30–50)         | 6559               | 38 (30–50)         | 6154    | <0.001 |

Figure 1. Changes in the median BLL of different age groups from 2011 to 2020. The seven colors represent seven age groups. Blue represents ~1 year group; Red represents ~2 years group; Green represents ~3 years group; Purple represents ~4 years group; Light blue represents ~5 years group; Orange represents ~6 years group; Navy blue represents ~7 years group.

3.2. Elevated BLLs

Because the standards are different between the Ministry of Health of China and the CDC of the United States, we analyzed the prevalence of two BLLs. The overall prevalence of BLLs ≥ 100 μg/L was 1.20%. The prevalence of BLLs ≥ 100 μg/L varied from 1.63% to 0.35% during the last decade. It was the lowest in 2020 and highest in 2015. There was no trend in prevalence from 2011 to 2015, but it has been decreasing year by year since 2015 (Figure 2A). The overall prevalence of BLLs ≥ 50 μg/L was 21.56%. The prevalence of BLLs ≥ 50 μg/L varied from 62.59% to 1.98% during the last decade, and it was highest in 2011 and lowest in 2020. There was a downward trend of the prevalence in general, and it presented a sharp fall from 2011 to 2014 (Figure 2B). The trend of change in the prevalence of BLLs ≥ 50 μg/L is consistent with that in the median BLLs.
To evaluate treatment efficiency, 73 participants were recruited into two groups. The first included 54 children with high blood lead (100 ≤ BLLs ≤ 199 μg/L), and the second included 19 children with mild lead poisoning (200 ≤ BLLs ≤ 249 μg/L). After a period of oral calcium supplement, the BLLs of the 73 children were retested, which was the basis for us to evaluate treatment efficiency. During the follow-up, 15 children had their BLLs reduced to blow 100 μg/L in the first group, and only three children had their BLLs reduced to blow 100 μg/L in the second group. The shortest time required for an effective treatment in the first and second groups was two and seven months, respectively. The interval from the beginning of treatment to the retesting of BLLs varied in each child, ranging from 1 month to 26 months with a mean of 8.6 months. The result exhibited no statistical difference between the two groups ($\chi^2 = 0.273, p = 0.601$). The median time required for an effective treatment was 18 months in the first group. The median time required for an effective treatment was not available in the second group (Figure 3).

Figure 3. Treatment efficiency of oral calcium supplements in children with high BLLs and mild lead poisoning.
3.4. Lead Exposure Disrupted Ca\textsuperscript{2+} Signals in Developing Cortical Neurons

A mechanistic study was performed on mice to further clarify the significant neurotoxicity of lead. Lead not only competes for calcium binding sites but also reduces the level of intracellular calcium \[14\], which prompted us to measure the acute effects of lead exposure on developing cortical neurons. The Ca\textsuperscript{2+} stain was used in coronal slices of mice on post-natal day 21. An assessment of the acute effects of lead on neuron Ca\textsuperscript{2+} signals was achieved via the continuous infusion of lead. Interestingly, we observed that lead exposure led to a gradual and persistent loss of Ca\textsuperscript{2+} signals in developing cortical neurons. All fluorescent patterns of the excited neurons indicated by the white arrows disappeared. The fluorescent intensity in the 100 \(\mu\)g/L group was lower than that of the 50 \(\mu\)g/L group and control group after lead exposure, and it did not recover even after the aCSF (including CaCl\textsubscript{2}) was switched back (i.e., the lead exposure was removed) (Figure 4). The change in fluorescence intensity in the 50 \(\mu\)g/L group was not observable. The fluorescent patterns of only a few of the excited neurons indicated by the white arrows disappeared.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{Figure_4.png}
\caption{Representative confocal images of Ca\textsuperscript{2+} in the brain slices. The cells indicated by the white arrows are neurons with reduced Ca\textsuperscript{2+} signaling after lead exposure. Dynamic loss of Ca\textsuperscript{2+} fluorescence intensity can be observed from left to right: the left column shows the fluorescence intensity of brain slices before lead exposure, the middle column shows the fluorescence intensity after lead exposure, and the right column shows the fluorescence intensity after the removal of lead exposure. The control group was observed in aCSF. Scale bar, 50 \(\mu\)m.}
\end{figure}
4. Discussion

Lead has become known as a highly toxic element for children, as it has no known biological function. Child intoxication occurs through the air, water, and skin by inhaling polluted air or eating contaminated food. The clinical features of lead intoxication are non-specific and often go unrecognized [15]. We analyzed BLL data for 76,362 children, and the overall median BLL was 35 µg/L from 2011 to 2020. A downward trend in basic BLLs was observed. The BLLs of boys were higher than that of girls every year, which is consistent with the findings of a previous study [16]. The boy to girl ratio was the highest in 2019, but the median BLL was the second lowest. It suggested that the sex ratio is not the decisive factor in determining the median BLL. The BLLs increased with age, which suggests that lead accumulates in the body and has cumulative effects [17]. Sichuan Province is an area with low prevalence of BLL ≥ 100 µg/L; therefore, BLLs in children are significantly lower compared with the other parts of China. For example, the mean BLL was 44.75 µg/L in Wuhan among 15,536 children [18]. However, lead-poisoning prevention is still an urgent task in Sichuan Province when compared with developed countries [19,20].

Even at relatively low blood concentrations, shown significant associations have been shown between lead and such adverse effects as intellectual impairment, hyperactivity and lack of concentration, and damage to virtually all organ systems, including brain, heart, kidneys, liver, and the circulatory system. Elevated blood lead concentrations have also been associated with lowered birth weight, violent or aggressive behavior, hypertension, and so on [21]. The prevalence of children with BLL ≥ 100 µg/L was low [22], and this value did not decrease annually. Notably, the prevalence of children with BLL ≥ 100 µg/L was 0.6% in 2011; however, the BLL value was at its highest. This manifests two things: first, the basic BLLs of children in 2011 were relatively high, even though the prevalence of children with BLL ≥ 100 µg/L was low; second, children primarily exhibited BLL ≥ 100 µg/L owing to accidental lead exposure, which has little influence on the overall level of the whole population. The prevalence of children with BLL ≥ 50 µg/L was the highest in 2011 and lowest in 2020. It has gradually decreased in the past decade. The trend of change in the prevalence of BLLs ≥ 50 µg/L is consistent with that in the median BLLs. The prevalence of BLLs ≥ 50 µg/L indicates the change of median BBLs more accurately than the prevalence of BLLs ≥ 100 µg/L. Our results accurately represent the BLLs of children in Sichuan Province. With the improvement of living standards, people pay increasing attention to lead poisoning; thus, the BLLs of children and the prevalence of children with BLL ≥ 50 µg/L are well controlled.

The BLLs of children have gradually decreased in the past decade. In regards to the previously mentioned guidelines issued by the Ministry of Health, China, since the prevention, diagnosis, and treatment of lead poisoning was based on the situation in China in 2006, the content of articles may require updating. Moreover, the documents did not include the possibility of standardized nutritional interventions for children with high blood lead and mild lead poisoning. Meanwhile, this study explored the utility of calcium supplements in the treatment of lead poisoning. The median time required for the effective treatment of children with high blood lead using a calcium supplement was 18 months. The median time for the effective treatment of children with mild lead poisoning was not available owing to the small number of subjects and short follow-ups. The shortest time required for an effective treatment in children with mild lead poisoning was seven months, which was longer than two months. It was assumed that the median time required for the effective treatment of children with mild lead poisoning must be longer than that of children with high blood lead. The result exhibited no statistical difference between the two groups. This is obviously unreasonable and the result may be influenced by the small number of subjects or short follow-ups. Lead can damage the nervous system in the development period, and long-term exposure is bound to cause immeasurable effects on the nervous systems of children. The duration of treatment should be as short as possible. Chelation therapy has been proven to be a rapid and effective treatment. Maybe we can adjust the BLL for chelation therapy appropriately; for example, chelation therapy was
adopted when the BLL ≥ 150 µg/L. We intended for the results of this study to highlight the need for a new standard treatment that will shorten the treatment time as much as possible.

Lead is regarded as an important environmental risk factor leading to irreversible neurological disorders, such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, attention deficit hyperactivity disorder, etc. [23]. It can cause a variety of adverse outcome on central nervous system (CNS). Lead mimics the function of Ca^{2+} when it enters the body, which results in a range of specific documented long-term deleterious effects [24], such as cognitive decline, hypertension, and cardiovascular disease [17]. For children, the most serious effect caused by lead is neurological damage. Using Ca^{2+} imaging experiments, we have dynamically observed that acute lead exposure leads to a rapid and irreversible decrease in the concentration of Ca^{2+} in neurons in the cerebral cortex. The potential mechanism that causes this is as follows: lead binds to the selectivity filter of the voltage-gated calcium channels, and when the binding affinity of lead for the binding site is high, some Pb^{2+} may enter the cell through these channels. Elevated intracellular lead levels result in the substitution of Ca^{2+}, and it blocks the voltage-gated calcium channels [24]. Thus, after the lead exposure was removed, and CaCl_2 was added as a treatment, the neurons did not recover within a short period of time. Although only a limited amount of evidence directly suggested loss of Ca^{2+} in lead-induced neurological disorders, loss of Ca^{2+} may still constitute important aspects connecting environmental lead exposure and CNS-related disease.

5. Conclusions

This study focused on the current BLLs of children in Sichuan Province and the antagonistic effects between lead and calcium regarding treatment and neurotoxicity. The BLLs of children in Sichuan Province have clearly decreased recently, and only 0.35% of children have BLLs higher than 100 µg/L in 2020. Sichuan Province is now a low-epidemic area in terms of lead pollution. The oral calcium supplement treatment given to children with high BLLs and mild lead poisoning takes a long time to remove lead. Therefore, a new strategy is urgently needed to shorten the treatment time. We also demonstrated the neurotoxicity of lead using Ca^{2+} imaging, which dynamically displayed a rapid and irreversible decrease in the concentration of Ca^{2+} in neurons. We propose that these results can provide support for local illness prevention and policy making. Our study has some limitations. First, as all subjects were outpatients for regular checkups in our hospital, there was a selection bias in this study. Second, the median time for effective treatment of children with mild lead poisoning was not available owing to the small number of subjects and short follow-ups. In future research, we will expand the follow-up population and extend the duration of follow-up to obtain a more accurate median time for effective treatment. Further basic experiments will be carried out to further reveal the neurotoxic mechanism of lead by means of electrophysiological experiments, neurotransmitter content detection, and gene sequencing.

Author Contributions: Conceptualization, Y.D. and Y.J.; methodology, Y.D.; software, Y.D.; validation, Y.D., H.S. and Y.J.; formal analysis, Y.D.; investigation, Y.D.; resources, Y.D.; data curation, Y.D.; writing—original draft preparation, Y.D.; writing—review and editing, Y.D. and H.S.; visualization, Y.D.; supervision, H.S. and Y.J.; project administration, Y.J.; funding acquisition, Y.J. All authors have read and agreed to the published version of the manuscript.

Funding: This work was supported by Department of Science and Technology of Sichuan Province (grant number 2020YFS0100) and Bureau of Science and Technology of Chengdu (grant number 2019-YF05-01178-SN).

Institutional Review Board Statement: Ethics approval was obtained from the Medical Ethics Committee of West China Second University Hospital of Sichuan University (protocol 2021176). All experiments using mice were approved by the Animal Research Committee at the West China Second University Hospital of Sichuan University (protocol 2021048A).
Informed Consent Statement: Patient consent was waived, as participating patients cannot be identified.

Data Availability Statement: All relevant data from this study are available from the authors.

Acknowledgments: We are grateful for the pediatricians in West China Second University Hospital of Sichuan University for their instructive suggestions and helpful comments.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Surkan, P.J.; Zhang, A.; Trachtenberg, F.; Daniel, D.B.; McKinlay, S.; Bellinger, D.C. Neuropsychological function in children with blood lead levels <10 microg/dL. Neurotoxicology 2007, 28, 1170–1177. [CrossRef] [PubMed]

2. Glenn, B.S.; Bandeen-Roche, K.; Lee, B.K.; Weaver, V.M.; Todd, A.C.; Schwartz, B.S. Changes in systolic blood pressure associated with lead in blood and bone. Epidemiology 2006, 17, 538–544. [CrossRef] [PubMed]

3. Cleveland, L.M.; Minter, M.L.; Cobb, K.A.; Scott, A.A.; German, V.F. Lead hazards for pregnant women and children: Part 1: Immigrants and the poor shoulder most of the burden of lead exposure in this country. Part 1 of a two-part article details how exposure happens, whom it affects, and the harm it can do. Am. J. Nurs. 2008, 108, 40–49. [CrossRef] [PubMed]

4. Abadin, H.; Ashizawa, A.; Stevens, Y.W.; Llados, F.; Diamond, G.; Sage, G.; Citra, M.; Quinones, A.; Bosch, S.J.; Swarts, S.G. Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles. In Toxicological Profile for Lead; Agency for Toxic Substances and Disease Registry (US): Atlanta, GA, USA, 2007.

5. Bellinger, D.C. Lead neurotoxicity in children: Decomposing the variability in dose-effect relationships. Am. J. Ind. Med. 2007, 50, 720–728. [CrossRef] [PubMed]

6. Müller, Y.M.; Rivero, L.B.; Carvalho, M.C.; Kobus, K.; Farina, M.; Nazari, E.M. Behavioral impairments related to lead-induced developmental neurotoxicity in chicks. Arch. Toxicol. 2008, 82, 445–451. [CrossRef] [PubMed]

7. National Health Commission of the People’s Republic of China. The Children Lead Acidosis and Lead Poisoning Prevention and Control Guide and Children’s Blood Lead and Lead Poisoning Classification Principles. Available online: http://www.nhc.gov.cn/wjw/gfxwj/201304/a0f2eb3564bd46ae8c75645631aaf6d.shtml (accessed on 23 September 2021).

8. Centers for Disease Control and Prevention. What Do Parents Need to Know to Protect Their Children? Available online: http://www.cdc.gov/nceh/lead/ACCLPP/blood_lead_levels.htm (accessed on 23 September 2021).

9. Ettinger, A.S.; Leonard, M.L.; Mason, J. CDC’s Lead Poisoning Prevention Program: A Long-standing Responsibility and Commitment to Protect Children From Lead Exposure. J. Public Health Manag. Pract. 2019, 25 (Suppl. S1), S5–S12. [CrossRef] [PubMed]

10. Kern, M.; Wisniewski, M.; Cabell, L.; Audesirk, G. Inorganic lead and calcium interact positively in activation of calmodulin. Neurotoxicology 2000, 21, 353–363. [CrossRef]

11. Westerink, R.H.; Klompackers, A.A.; Westenberg, H.G.; Vijverberg, H.P. Signaling pathways involved in Ca2+- and Pb2+-induced vesicular catecholamine release from rat PC12 cells. Brain Res. 2002, 957, 25–36. [CrossRef] [PubMed]

12. Sun, Z.; Südhof, T.C. A simple Ca(2+)-imaging approach to neural network analyses in cultured neurons. J. Neurosci. Methods 2021, 349, 109041. [CrossRef] [PubMed]

13. Garza, A.; Vega, R.; Soto, E. Cellular mechanisms of lead neurotoxicity. Med. Sci. Monit. 2006, 12, RA57–RA65. [PubMed]

14. Raciti, M.; Ceccatelli, S. Epigenetic mechanisms in developmental neurotoxicity. Neurotoxicol. Teratol. 2018, 66, 94–101. [CrossRef] [PubMed]

15. Wang, X.; Ding, N.; Tucker, K.L.; Weisskopf, M.G.; Sparrow, D.; Hu, H.; Park, S.K. A Western Diet Pattern Is Associated with Higher Concentrations of Blood and Bone Lead among Middle-Aged and Elderly Men. J. Nutr. 2017, 147, 1374–1383. [CrossRef] [PubMed]

16. Green, D.; Sullivan, M.; Cooper, N.; Dean, A.; Marquez, C. A Pilot Study of Children’s Blood Lead Levels in Mount Isa, Queensland. Int. J. Environ. Res. Public Health 2017, 14, 1567. [CrossRef] [PubMed]

17. Li, Y.; Wu, S.; Xiang, Y.; Liang, X. An investigation of outpatient children’s blood lead level in Wuhan China. PLoS ONE 2014, 9, e95284. [CrossRef] [PubMed]

18. Ettinger, A.S.; Leonard, M.L.; Mason, J. CDC’s Lead Poisoning Prevention Program: A Long-standing Responsibility and Commitment to Protect Children From Lead Exposure. J. Public Health Manag. Pract. 2019, 25 (Suppl. S1), S5–S12. [CrossRef] [PubMed]

19. Health Canada. Second Report on Human Biomonitoring of Environmental Chemicals in Canada. Available online: https://www.canada.ca/en/health-canada/services/environmental-workplace-health/reports-publications/environmental-contaminants/second-report-human-biomonitoring-environmental-chemicals-canada-health-canada-2013.html (accessed on 23 September 2021).

20. Mathec, A.; Schirnding, Y.V.; Montgomery, M.; Röllin, H. Lead Poisoning in South African Children: The Hazard is at Horne. Rev. Environ. Health 2021, 19, 347–362. [CrossRef] [PubMed]
22. Shi, H.; Jiang, Y.M.; Li, J.Y.; Liu, F.; Wang, H.; Yu, F.; Yang, H. Environmental lead exposure among children in Chengdu, China, 2007–2009. *Biol. Trace Elem. Res.* 2011, 143, 97–102. [CrossRef] [PubMed]

23. Wang, T.; Zhang, J.; Xu, Y. Epigenetic Basis of Lead-Induced Neurological Disorders. *Int. J. Environ. Res. Public Health* 2020, 17, 4878. [CrossRef] [PubMed]

24. Florea, A.-M.; Taban, J.; Varghese, E.; Alost, B.T.; Moreno, S.; Büsselberg, D. Lead (Pb$^{2+}$) neurotoxicity: Ion-mimicry with calcium (Ca$^{2+}$) impairs synaptic transmission. A review with animated illustrations of the pre- and post-synaptic effects of lead. *J. Local Glob. Health Sci.* 2013, 4. [CrossRef]